Pleura and Peritoneum最新文献_第4页

Frontmatter 头版头条

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2023-frontmatter1

引用次数: 0

Implementation of an enhanced recovery program for complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a referral center: a case control prospective study. 在转诊中心实施完全细胞减少手术和腹腔内热化疗的增强恢复计划:一项病例对照前瞻性研究。

IF 1.8

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2022-0133

Diane Charleux-Muller, Thibaut Fabacher, Benoit Romain, Nicolas Meyer, Cécile Brigand, Jean-Baptiste Delhorme

{"title":"Implementation of an enhanced recovery program for complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a referral center: a case control prospective study.","authors":"Diane Charleux-Muller, Thibaut Fabacher, Benoit Romain, Nicolas Meyer, Cécile Brigand, Jean-Baptiste Delhorme","doi":"10.1515/pp-2022-0133","DOIUrl":"https://doi.org/10.1515/pp-2022-0133","url":null,"abstract":"Objectives: Current recommendations regarding enhanced recovery programs (ERPs) after complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are based on a low level of evidence. The aim of this study is to evaluate the effect of implementing an adapted ERP for CCRS and HIPEC in a referral center.Methods: We conducted a study with a prospective group of 44 patients (post-ERP group) who underwent CCRS with HIPEC between July 2016 and June 2018, the period during which ERP was implemented. This group was compared to a second retrospective group of 21 patients who underwent CCRS with HIPEC between June 2015 and June 2016, during which ERP was not yet implemented (pre-ERP group).Results: The ERP compliance rate was 65% in the post-ERP group. The hospital length of stay (HLS) was shorter in the post-ERP group: 24.9 days (IQR 11-68, pre-ERP group) vs. 16.1 days (IQR 6-45, post-ERP group), as was the major morbidity rate (pre-ERP group=33.3% vs. post-ERP group=20.5%). The nasogastric tube, urinary catheter and abdominal drains were all retrieved faster in the post-ERP group.Conclusions: The implementation of an adapted ERP after CCRS with HIPEC procedures reduces morbidity and shortens the HLS.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"11-18"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9636875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A study of somatic BRCA variants and their putative effect on protein properties in malignant mesothelioma. 体细胞BRCA变异及其对恶性间皮瘤蛋白特性的影响的研究。

IF 1.8

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2023-0003

Kritika Krishnamurthy, Kei Shing Oh, Sarah Alghamdi, Vathany Sriganeshan, Robert Poppiti

{"title":"A study of somatic BRCA variants and their putative effect on protein properties in malignant mesothelioma.","authors":"Kritika Krishnamurthy, Kei Shing Oh, Sarah Alghamdi, Vathany Sriganeshan, Robert Poppiti","doi":"10.1515/pp-2023-0003","DOIUrl":"https://doi.org/10.1515/pp-2023-0003","url":null,"abstract":"Objectives: The aim of this study is to analyze the prevalence of somatic mutations in BRCA1 and BRCA2 in malignant mesothelioma and their putative impact on protein properties.Methods: Eighteen cases of malignant mesothelioma were retrieved from the archives and for next generation sequencing analysis of BRCA1 and BRCA2 genes. Variants were analyzed using Ensembl VEP17, Polyphen 2.0 software, SIFT software, MutpredV2, and SWISS-MODEL homology-modeling pipeline server.Results: BRCA2 variants were found in significantly higher percentage (22%) of cases (p=0.02). Five missense variants were identified. These were p.A2351P, p.T2250A, p.A895V, pG1771D, and p.R2034C. The SIFT scores of all except one were ≥ 0.03. The Polyphen scores of these four alterations were ≤0.899. In case of p.A2315, the SIFT score was 0.01, while the Polyphen 2 score was 0.921. MutPred2 scores were ≤0.180 for all. Loss of intrinsic disorder was predicted (Pr=0.32, p=0.07) for p.R2034C, while gain of intrinsic disorder was predicted for p.A2351P (Pr=0.36, p=0.01) and p.G1771D (Pr=0.34, p=0.02).Conclusions: BRCA2 somatic variants were identified in 22% cases of malignant mesotheliomas in this study. The variants localize more frequently to the disordered regions of the protein and are predicted to affect the level of disorder.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"19-25"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9336163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei. 确定报告腹膜假性黏液瘤临床和放射学资料的最小数据集。

IF 1.8

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2022-0200

Thale D J H Patrick-Brown, Faheez Mohamed, Andrew Thrower, Annette Torgunrud, Sarah Cosyns, Emel Canbay, Laurent Villeneuve, Kjersti Flatmark, Andreas Brandl

{"title":"Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei.","authors":"Thale D J H Patrick-Brown, Faheez Mohamed, Andrew Thrower, Annette Torgunrud, Sarah Cosyns, Emel Canbay, Laurent Villeneuve, Kjersti Flatmark, Andreas Brandl","doi":"10.1515/pp-2022-0200","DOIUrl":"https://doi.org/10.1515/pp-2022-0200","url":null,"abstract":"Objectives: Pseudomyxoma peritonei (PMP) is a rare cancer currently affecting over 11,736 patients across Europe. Since PMP is so uncommon, collaboration between scientific centers is key to discovering the mechanisms behind the disease, efficient treatments, and targets pointing to a cure. To date, no consensus has been reached on the minimum data that should be collected during PMP research studies. This issue has become more important as biobanking becomes the norm. This paper begins the discussion around a minimum data set that should be collected by researchers through a review of available clinical trial reports in order to facilitate collaborative efforts within the PMP research community.Content: A review of articles from PubMed, CenterWatch, ClinicalTrials.gov and MedRxiv was undertaken, and clinical trials reporting PMP results selected.Summary: There is a core set of data that researchers report, including age and sex, overall survival, peritoneal cancer index (PCI) score, and completeness of cytoreduction, but after this, reports become variable.Outlook: Since PMP is a rare disease, it is important that reports include as large of a number of standardised data points as possible. Our research indicates that there is still much ground to cover before this becomes a reality.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9336166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histological tumor response predicts clinical outcome in patients with colorectal peritoneal metastasis treated with preoperative chemotherapy followed by cytoreduction and HIPEC. 组织学肿瘤反应预测术前化疗后细胞减少和HIPEC治疗的结直肠腹膜转移患者的临床结果。

IF 1.8

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2022-0117

Isa Valéria Ferreira de Sousa, Joanne M D Lopes, Jorge P M Nogueiro, Teresa R Costa, Laura E R Barbosa, Marisa M M Aral

{"title":"Histological tumor response predicts clinical outcome in patients with colorectal peritoneal metastasis treated with preoperative chemotherapy followed by cytoreduction and HIPEC.","authors":"Isa Valéria Ferreira de Sousa, Joanne M D Lopes, Jorge P M Nogueiro, Teresa R Costa, Laura E R Barbosa, Marisa M M Aral","doi":"10.1515/pp-2022-0117","DOIUrl":"https://doi.org/10.1515/pp-2022-0117","url":null,"abstract":"Objectives: Up to one quarter of the patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PM). The aims of this retrospective study were to characterize the histological response of the PM of CRC to preoperative chemotherapy and evaluate the potential prognostic value, in terms of survival.Methods: This retrospective unicentric study evaluated a group of 30 patients treated between 2010 and 2020 at the São João University Hospital Center with preoperative chemotherapy, followed by cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy. The evaluation of the histological response was done using two scores: the tumor regression grading (TRG) and the peritoneal regression grading score (PRGS).Results: Mean post-procedure survival is higher in the PRGS 1-2 group (74.19 months) vs. the PRGS 3-4 group (25.27 months) (p=0.045), as well as in the TRG 1-2 group (74.58 months) vs. TRG 4-5 (25.27 months) (p=0.032). As for progression-free survival (PFS), the PRGS 1-2 group had a mean value of 58.03 months vs. PRGS 3-4 which had 11.67 months (p=0.002). Similar was observed with the TRG 1-2 group, which had a mean PFS of 61.68 months vs. TRG 4-5 with 11.67 months (p=0.003).Conclusions: A better histological response to preoperative chemotherapy, represented as a lower PRGS and TRG value, is associated with longer post-procedure survival and progression-free survival in this group of patients. That is, these two scores have prognostic value.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"37-44"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9336168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ISSPP CONGRESS 2022 3RD CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF PLEURA AND PERITONEUM. 国际胸膜和腹膜研究学会第三届大会。

IF 1.8

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2023-0010

引用次数: 1

Survival benefits with EPIC in addition to HIPEC for low grade appendiceal neoplasms with pseudomyxoma peritonei: a propensity score matched study. 低级别阑尾肿瘤伴腹膜假性黏液瘤，EPIC和HIPEC的生存获益:一项倾向评分匹配研究

IF 1.8

Pleura and Peritoneum Pub Date : 2023-03-01 DOI: 10.1515/pp-2022-0205

Raymond Hayler, Kathleen Lockhart, Shoma Barat, Ernest Cheng, Jasmine Mui, Raphael Shamavonian, Nima Ahmadi, Nayef Alzahrani, Winston Liauw, David Morris

{"title":"Survival benefits with EPIC in addition to HIPEC for low grade appendiceal neoplasms with pseudomyxoma peritonei: a propensity score matched study.","authors":"Raymond Hayler, Kathleen Lockhart, Shoma Barat, Ernest Cheng, Jasmine Mui, Raphael Shamavonian, Nima Ahmadi, Nayef Alzahrani, Winston Liauw, David Morris","doi":"10.1515/pp-2022-0205","DOIUrl":"https://doi.org/10.1515/pp-2022-0205","url":null,"abstract":"Objectives: Appendiceal cancer is a rare malignancy, occurring in roughly 1.2 per 100,000 per year. Low grade appendiceal neoplasams (LAMN) in particular can lead to pseudomyxoma peritonei (PMP), and respond poorly to systemic chemotherapy. Standard treatment includes cytoreduction surgery (CRS) with addition of heated intraoperative peritoneal chemotherapy (HIPEC). Several centres include early postoperative intraperitoneal chemotherapy (EPIC) however; the literature is mixed on the benefits. We aim to examine the benefits of additional EPIC through a propensity-matched analysis.Methods: Patients with LAMN with PMP who underwent cytoreductive surgery at St George hospital between 1996 and 2020 were included in this retrospective analysis. Propensity score matching was performed with the following used to identify matched controls; sex, age, American Society of Anesthesiologists (ASA) grade, peritoneal cancer index (PCI) and morbidity grade. Outcomes measured included length of stay and survival.Results: A total of 224 patients were identified of which 52 received HIPEC alone. Propensity matching was performed to identify 52 matched patients who received HIPEC + EPIC. Those receiving HIPEC + EPIC were younger at 54.3 vs. 58.4 years (p=0.044). There was a median survival benefit of 34.3 months for HIPEC + EPIC (127.3 vs. 93.0 months, p=0.02). Median length of stay was higher in those who received EPIC (25.0 vs. 23.5 days, p=0.028).Conclusions: In LAMN with PMP, the addition of EPIC to HIPEC with CRS improves overall survival in propensity score matched cases but results in prolonged hospitalisation. The use of EPIC should still be considered in selected patients.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"27-35"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9336169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erector spinae plane blocks for day-case medical thoracoscopy: a pilot clinical study. 直立者脊柱平面块用于日间医学胸腔镜检查:一项试点临床研究。

IF 1.8

Pleura and Peritoneum Pub Date : 2022-12-01 DOI: 10.1515/pp-2022-0115

Jamie McPherson, Edward Halvey, Avinash Aujayeb

{"title":"Erector spinae plane blocks for day-case medical thoracoscopy: a pilot clinical study.","authors":"Jamie McPherson, Edward Halvey, Avinash Aujayeb","doi":"10.1515/pp-2022-0115","DOIUrl":"https://doi.org/10.1515/pp-2022-0115","url":null,"abstract":"Objectives: Erector spinae plane (ESP) blocks are a regional anaesthetic technique used for pain relief in thoracic procedures. Our centre has recently begun using ESP blocks pre-medical thoracoscopy for analgesia.Methods: Nine patients undergoing MT from September 2021 to February 2022 were included. Opioid use and depth of required sedation was recorded. Pre and post pain scores and at home were recorded by interview and review of charts. A functional pain questionnaire was administered via telephone.Results: Average greatest depth of sedation using propofol was 1.92 (standard error of mean [SEM] 0.27), with remifentanil 2.52 (SEM 0.46). 78% required oral analgesia on day 0 post discharge. 55% required oral analgesia on post-op day 1. Patients used an average of 3.33 mg oral morphine (SEM 2.35) in hospital, and 3 mg (SEM 2) on post-op day 1. Periprocedural pain scores were 0.66 (SEM 0.27). Pain scores in recovery were 1.56 (SEM 0.76). Pain scores 3-12 h post discharge were 3.56 (SEM 0.7), while pain scores on post-op day 1 were significantly higher at 5.56 (SEM 0.90) (Figure 1). Functional pain scoring showed patients doing activities of daily living well with a good ability to breathe and cough. All felt that their pain was well controlled on the day of the procedure and at home. No complications were reported.Conclusions: ESP blocks provide good analgesia. Pain scores showed significant analgesic effect lasting several hours. The project showed pain outcomes and patient acceptability were good for the use of regional anaesthesia.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"187-190"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Cytologic features of epithelioid gastrointestinal stromal tumor in a pleural effusion. A diagnostic challenge. 胸腔积液中上皮样胃肠道间质瘤的细胞学特征。诊断上的挑战。

IF 1.8

Pleura and Peritoneum Pub Date : 2022-12-01 DOI: 10.1515/pp-2022-0196

Mariel Valdivia-Mazeira, Carlos Gordillo, Zehra Avan, Lidia Castillo-Gázquez, José A Jiménez-Heffernan

引用次数: 1

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review. 细胞减少手术(CRS)和腹腔热化疗(HIPEC)治疗伴有腹膜转移的小肠腺癌:一项系统综述。

IF 1.8

Pleura and Peritoneum Pub Date : 2022-12-01 DOI: 10.1515/pp-2022-0121

Vicky Chen, Morgan Jones, Lauren Cohen, Wilson Yang, Jasman Bedi, Helen M Mohan, Sameer S Apte, José Tomas Larach, Michael Flood, Alexander Heriot, Joseph Kong, Satish Warrier

{"title":"Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review.","authors":"Vicky Chen, Morgan Jones, Lauren Cohen, Wilson Yang, Jasman Bedi, Helen M Mohan, Sameer S Apte, José Tomas Larach, Michael Flood, Alexander Heriot, Joseph Kong, Satish Warrier","doi":"10.1515/pp-2022-0121","DOIUrl":"https://doi.org/10.1515/pp-2022-0121","url":null,"abstract":"Objectives: Small bowel adenocarcinoma (SBA) with peritoneal metastasis (PM) is rare and despite treatment with systemic chemotherapy, the prognosis is poor. However, there is emerging evidence that cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a survival benefit over systemic therapy alone. This systematic review will assess the effectiveness of CRS-HIPEC for SBA-PM.Content: Three databases were searched from inception to 11/10/21. Clinical outcomes were extracted and analysed.Summary: A total of 164 cases of SBA-PM undergoing CRS-HIPEC were identified in 12 studies. The majority of patients had neoadjuvant chemotherapy (87/164, 53%) and complete cytoreduction (143/164, 87%) prior to HIPEC. The median overall survival was 9-32 months and 5-year survival ranged from 25 to 40%. Clavien-Dindo grade III/IV morbidity ranged between 19.1 and 50%, while overall mortality was low with only 3 treatment-related deaths.Outlook: CRS-HIPEC has the potential to improve the overall survival in a highly selected group of SBA-PM patients, with 5-year survival rates comparable to those reported in colorectal peritoneal metastases. However, the expected survival benefits need to be balanced against the intrinsic risk of morbidity and mortality associated with the procedure. Further multicentre studies are required to assess the safety and feasibility of CRS-HIPEC in SBA-PM to guide best practice management for this rare disease.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"159-167"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1